Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2026)

Alnylam Pharmaceuticals' Current Leases history runs 8 years deep, the most recent figure standing at $45.7 million for Q1 2026.

• Quarterly Current Leases fell 0.76% year-over-year to $45.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.7 million (down 0.76% YoY) and the FY2025 annual result came in at $45.5 million, up 8.67% from the prior year.
• Current Leases was $45.7 million for Q1 2026 at Alnylam Pharmaceuticals, roughly flat from $45.5 million in the prior quarter.
• Across five years, Current Leases topped out at $46.1 million in Q2 2025 and bottomed at $41.2 million in Q2 2022.
• A 5-year average of $42.9 million and a median of $42.0 million in 2022 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases dropped 3.21% — and 2025, when it rose 10.66%.
• Alnylam Pharmaceuticals' Current Leases stood at $42.0 million in 2022, then decreased by 1.09% to $41.5 million in 2023, then advanced by 0.91% to $41.9 million in 2024, then increased by 8.67% to $45.5 million in 2025, then grew by 0.31% to $45.7 million in 2026.
• Business Quant data shows ALNY's Current Leases at $45.7 million in Q1 2026, $45.5 million in Q4 2025, and $44.8 million in Q3 2025.